SAB Biotherapeutics Statistics

Total Valuation

SABS has a market cap or net worth of $13.66 million. The enterprise value is -$12.22 million.

Market Cap	13.66M
Enterprise Value	-12.22M

Important Dates

The next estimated earnings date is Monday, May 19, 2025, after market close.

Earnings Date	May 19, 2025
Ex-Dividend Date	n/a

Share Statistics

SABS has 9.23 million shares outstanding. The number of shares has increased by 74.13% in one year.

Current Share Class	9.23M
Shares Outstanding	9.23M
Shares Change (YoY)	+74.13%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	16.50%
Owned by Institutions (%)	21.66%
Float	6.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.44
Forward PS	11.96
PB Ratio	0.37
P/TBV Ratio	0.37
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.69, with a Debt / Equity ratio of 0.12.

Current Ratio	3.69
Quick Ratio	3.46
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-159.11

Financial Efficiency

Return on equity (ROE) is -174.73% and return on invested capital (ROIC) is -105.52%.

Return on Equity (ROE)	-174.73%
Return on Assets (ROA)	-78.80%
Return on Invested Capital (ROIC)	-105.52%
Return on Capital Employed (ROCE)	-115.11%
Revenue Per Employee	$26,539
Profits Per Employee	-$799,428
Employee Count	57
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -64.93% in the last 52 weeks. The beta is 0.45, so SABS's price volatility has been lower than the market average.

Beta (5Y)	0.45
52-Week Price Change	-64.93%
50-Day Moving Average	2.06
200-Day Moving Average	2.82
Relative Strength Index (RSI)	37.64
Average Volume (20 Days)	37,781

Short Selling Information

The latest short interest is 114,974, so 1.25% of the outstanding shares have been sold short.

Short Interest	114,974
Short Previous Month	124,951
Short % of Shares Out	1.25%
Short % of Float	1.71%
Short Ratio (days to cover)	1.50

Income Statement

In the last 12 months, SABS had revenue of $1.51 million and -$45.57 million in losses. Loss per share was -$5.28.

Revenue	1.51M
Gross Profit	-25.38M
Operating Income	-51.78M
Pretax Income	-40.32M
Net Income	-45.57M
EBITDA	-46.91M
EBIT	-51.78M
Loss Per Share	-$5.28

Full Income Statement

Balance Sheet

The company has $30.40 million in cash and $4.52 million in debt, giving a net cash position of $25.88 million or $2.80 per share.

Cash & Cash Equivalents	30.40M
Total Debt	4.52M
Net Cash	25.88M
Net Cash Per Share	$2.80
Equity (Book Value)	36.90M
Book Value Per Share	4.00
Working Capital	23.72M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$38.21 million and capital expenditures -$349,749, giving a free cash flow of -$38.56 million.

Operating Cash Flow	-38.21M
Capital Expenditures	-349,749
Free Cash Flow	-38.56M
FCF Per Share	-$4.18

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-3,422.67%
Pretax Margin	-3,012.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

SABS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-74.13%
Shareholder Yield	n/a
Earnings Yield	-333.60%
FCF Yield	-282.27%

Analyst Forecast

The average price target for SABS is $12.40, which is 737.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$12.40
Price Target Difference	737.84%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	78.31%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 5, 2024. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Jan 5, 2024
Split Type	Reverse
Split Ratio	0.1:1

Scores

SABS has an Altman Z-Score of -4.15 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.15
Piotroski F-Score	2